Elexacaftor/tezacaftor/ivacaftor improves nasal nitric oxide in patients with cystic fibrosis

Nasal nitric oxide (nNO) is known to be reduced in people with primary ciliary dyskinesia (PwPCD) and the measurement is used in PCD's diagnostic workup [1]. It was found, that nNO is not only reduced in PCD, but also in people with cystic fibrosis (PwCF), and in chronic rhinosinusitis (CRS) even without underlying CF and nasal polyps [2,3]. It is increased in people with allergic rhinitis and asthma compared to healthy controls (HC) [2]. People with reduced nNO levels and a history of lung disease should therefore not only be evaluated for PCD, but also for CF and other diseases associated with chronic inflammation of the paranasal sinuses.

Source: Journal of Cystic Fibrosis - March 21, 2024 Category: Respiratory Medicine Authors: Charlotte O. Pioch, Niklas Ziegahn, Christine Allomba, Leonie M. Busack, Alexandra N. Schnorr, Apolline Tosolini, Bent R. Fuhlrott, Styliani Zagkla, Till Othmer, Zulfiya Syunyaeva, Simon Y. Graeber, Mehrak Yoosefi, Stephanie Thee, Eva Steinke, Jobst R öh Tags: Original Article Source Type: research